泊沙康唑在治疗口腔念珠菌病中的作用。
Role of posaconazole in the treatment of oropharyngeal candidiasis.
机构信息
Section of Infectious Diseases and Department of Medicine.
出版信息
Infect Drug Resist. 2010;3:45-51. doi: 10.2147/idr.s10588. Epub 2010 Mar 11.
Abstract
Posaconazole is the newest azole antifungal approved by the US Food and Drug Administration, and possesses a broad spectrum of activity against numerous yeasts and filamentous fungi. It is available as an oral suspension and is generally well tolerated by patients, but gastrointestinal absorption is sometimes inadequate and remains a clinical concern in treating deep-seated infections. It is used routinely and effectively for the prophylaxis of invasive fungal infections in immunosuppressed hosts and is an effective treatment of oropharyngeal candidiasis, including azole-resistant disease.
摘要
泊沙康唑是美国食品药品监督管理局批准的最新唑类抗真菌药物，对多种酵母和丝状真菌具有广泛的活性。它有口服混悬剂，一般患者耐受性良好，但胃肠道吸收有时不足，在治疗深部真菌感染时仍然是一个临床关注的问题。它被常规有效地用于免疫抑制宿主侵袭性真菌感染的预防，也是口咽念珠菌病（包括唑类耐药疾病）的有效治疗药物。
相似文献
1
Role of posaconazole in the treatment of oropharyngeal candidiasis.
Infect Drug Resist. 2010;3:45-51. doi: 10.2147/idr.s10588. Epub 2010 Mar 11.
2
Posaconazole: an extended-spectrum triazole antifungal agent.
Clin Ther. 2007 Sep;29(9):1862-86. doi: 10.1016/j.clinthera.2007.09.015.
3
Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.
Clin Infect Dis. 2007 Dec 15;45(12):1610-7. doi: 10.1086/523576.
4
Posaconazole: when and how? The clinician's view.
Mycoses. 2012 Mar;55(2):110-22. doi: 10.1111/j.1439-0507.2011.02061.x. Epub 2011 Jul 18.
5
Posaconazole in the management of refractory invasive fungal infections.
Ther Clin Risk Manag. 2008 Aug;4(4):747-58. doi: 10.2147/tcrm.s3329.
6
Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole.
Infect Drug Resist. 2015 Sep 9;8:321-31. doi: 10.2147/IDR.S65592. eCollection 2015.
7
Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections.
Semin Respir Crit Care Med. 2015 Oct;36(5):767-85. doi: 10.1055/s-0035-1562902. Epub 2015 Sep 23.
8
Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.
Can J Infect Dis Med Microbiol. 2008 Jul;19(4):297-305. doi: 10.1155/2008/825901.
9
New antifungal agents.
Dermatol Clin. 2003 Jul;21(3):565-76. doi: 10.1016/s0733-8635(03)00024-x.
10
Posaconazole : a review of its use in the prophylaxis of invasive fungal infections.
Drugs. 2008;68(7):993-1016. doi: 10.2165/00003495-200868070-00008.
引用本文的文献
1
Dual-Cross-Linked Alginate Hydrogels as a Strategy to Improve the Antifungal Properties of Posaconazole.
Pharmaceutics. 2025 Aug 14;17(8):1055. doi: 10.3390/pharmaceutics17081055.
2
Development and Evaluation of Oro-Mucosal Drug Delivery System for the Effective Management of Oropharyngeal Candidiasis: An Animal Study.
Cureus. 2025 May 29;17(5):e85040. doi: 10.7759/cureus.85040. eCollection 2025 May.
3
Enhanced antifungal activity of posaconazole against Candida auris by HIV protease inhibitors, atazanavir and saquinavir.
Sci Rep. 2024 Jan 18;14(1):1571. doi: 10.1038/s41598-024-52012-8.
4
Surfactin and Capric Acid Affect the Posaconazole Susceptibility of Strains with Altered Sterols and Sphingolipids Biosynthesis.
Int J Mol Sci. 2023 Dec 15;24(24):17499. doi: 10.3390/ijms242417499.
5
Comparative Efficacy of Antifungal Agents Used in the Treatment of Oropharyngeal Candidiasis among HIV-Infected Adults: A Systematic Review and Network Meta-Analysis.
J Fungi (Basel). 2021 Aug 5;7(8):637. doi: 10.3390/jof7080637.
6
Therapy of Skin, Hair and Nail Fungal Infections.
J Fungi (Basel). 2018 Aug 20;4(3):99. doi: 10.3390/jof4030099.
本文引用的文献
1
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.
Clin Infect Dis. 2009 Mar 1;48(5):503-35. doi: 10.1086/596757.
2
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
Antimicrob Agents Chemother. 2009 Mar;53(3):958-66. doi: 10.1128/AAC.01034-08. Epub 2008 Dec 15.
3
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
Antimicrob Agents Chemother. 2008 Jun;52(6):1929-33. doi: 10.1128/AAC.00130-08. Epub 2008 Apr 7.
4
Posaconazole: an extended-spectrum triazole antifungal agent.
Clin Ther. 2007 Sep;29(9):1862-86. doi: 10.1016/j.clinthera.2007.09.015.
5
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
N Engl J Med. 2007 Jan 25;356(4):348-59. doi: 10.1056/NEJMoa061094.
6
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
N Engl J Med. 2007 Jan 25;356(4):335-47. doi: 10.1056/NEJMoa061098.
7
Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.
Clin Infect Dis. 2007 Feb 15;44(4):607-14. doi: 10.1086/511039. Epub 2007 Jan 17.
8
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Antimicrob Agents Chemother. 2006 Jun;50(6):2009-15. doi: 10.1128/AAC.00163-06.
9
A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS.
Clin Infect Dis. 2006 Apr 15;42(8):1179-86. doi: 10.1086/501457. Epub 2006 Mar 14.
10
Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease.
J Clin Pharmacol. 2005 Feb;45(2):185-92. doi: 10.1177/0091270004271402.
Zotero 插件